Do NOT wait for the FDA to come a-knocking!
Pharmaceutical manufacturers often wait until after an FDA inspection to invest in quality assurance and regulatory compliance systems. However, investing in GMP Trends has proven to reduce 483’s and improve quality structures. Receiving an FDA 483 warning letter could lead to a shut down of a pharmaceutical manufacturing facility, and the resulting loss of production would have an extremely negative financial impact.
GMP in the pharmaceutical industry, or Good Manufacturing Practices, is nothing to be taken lightly. Learn from the mistakes of other manufacturers – Take a proactive approach to your quality systems and be prepared for your next inspection to prevent FDA 483 warning letters. Download a sample 483 report below to learn how GMP Trends can help you stay compliant withe FDA.
GMP Trends is an FDA Compliance Platform, providing relevant, real-time, and unbiased information reports trending USFDA 483-inspection observations. Our team understands the dynamic between the operational executives and the quality assurance teams, because we’e been there. Read the GMP Trends Report today, and leverage your efforts to safeguard product quality.
For over 40 years, GMP Trends has served as a regulatory intelligence resource for quality assurance, regulatory compliance, and R&D professionals in the pharmaceutical and medical device industries. GMP Trends’ Reports will help you formulate quality strategies, learn from the mistakes of other firms, and best prepare for stressful and tedious FDA inspections.
Sample 483 Report delivered to your inbox!
The twice-monthly GMP Trends report contains curated 483-observations, delivering only the essential information to keep you in compliance and up to date on the most recent actions of the FDA. Regain your Regulatory Compliance Focus with GMP Trends and download a sample 483 report from GMP Trends today.